Vivo Bio Tech Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, following a board meeting held on July 13, 2026. The meeting commenced at 7:00 PM and concluded at 7:30 PM.
Financial Performance (Standalone - Rs. in Lakhs)
Quarter Ended June 30, 2026:
- Revenue from operations: ₹1,427.97
- Other income: ₹5.54
- Total income: ₹1,433.51
- Total expenses: ₹1,399.65
- Consumption of raw materials: ₹286.13
- Purchase of traded goods: ₹472.98
- Employees cost: ₹353.17
- Depreciation and amortization: ₹123.76
- Finance cost: ₹264.11
- Administrative expenditure: Not separately quantified in standalone table
- Profit before tax: ₹33.86
- Tax expense: ₹15.10
- Current tax: ₹24.83
- Deferred tax: (₹9.74)
- Net profit after tax: ₹18.76
- Earnings per share (basic and diluted): ₹0.08
- Paid-up share capital: 2,219.06 lakh units (face value ₹10)
Comparative Figures:
- Q1 FY2025 (June 30, 2025): Net profit after tax ₹133.71 lakhs, EPS ₹0.74
- Q4 FY2026 (March 31, 2026): Net loss after tax ₹516.27 lakhs, EPS (₹2.52)
Consolidated Financial Results
Quarter Ended June 30, 2026:
- Revenue from operations: ₹1,413.94
- Other income: ₹5.54
- Total income: ₹1,419.48
- Total expenses: ₹1,385.95
- Decrease in stock in trade and WIP: (₹100.50)
- Purchase of traded goods: ₹286.13
- Employees cost: ₹459.29
- Depreciation and amortization: ₹353.17
- Finance cost: ₹123.76
- Administrative expenditure: ₹264.10
- Profit before tax: ₹33.53
- Tax expense: ₹15.10
- Current tax: ₹24.83
- Deferred tax: (₹9.74)
- Net profit after tax: ₹18.43
- Earnings per share (basic and diluted): ₹0.08
Key Notes and Disclosures
- The financial results were reviewed by the audit committee and approved by the board of directors on July 13, 2026.
- Results prepared in accordance with Indian Accounting Standards (Ind AS) and Regulation 33 of SEBI (LODR) Regulations, 2015.
- Consolidated results include subsidiaries: Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited, and Vivobio Consulting Services Private Limited.
- The company operates in a single segment: Bio Technology.
- Statutory auditors M/s. P. Murali & Co. issued limited review reports for both standalone and consolidated results, stating nothing has come to their attention suggesting material misstatement.
- Previous year's figures have been rearranged/regrouped where necessary.
- Financial results are available on BSE website (www.bseindia.com) and company website (www.vivobio.com).